Bone Metastasis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Bone Metastasis – Pipeline Review, H2 2017’, provides an overview of the Bone Metastasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Metastasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bone Metastasis

The report reviews pipeline therapeutics for Bone Metastasis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bone Metastasis therapeutics and enlists all their major and minor projects

The report assesses Bone Metastasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bone Metastasis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bone Metastasis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ablynx NV

Amgen Inc

Amura Holdings Ltd

BiologicsMD Inc

ChemoCentryx Inc

CSPC Pharmaceutical Group Limited

Deciphera Pharmaceuticals LLC

Eli Lilly and Co

Lupin Ltd

Mirati Therapeutics Inc

Oncobiologics Inc

Oncodrone BV

OPKO Health Inc

R Pharm

Redx Pharma Plc

Serene LLC

Taiho Pharmaceutical Co Ltd

Terpenoid Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Bone Metastasis - Overview 6

Bone Metastasis - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Bone Metastasis - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 18

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Bone Metastasis - Companies Involved in Therapeutics Development 25

Ablynx NV 25

Amgen Inc 25

Amura Holdings Ltd 26

BiologicsMD Inc 26

ChemoCentryx Inc 26

CSPC Pharmaceutical Group Limited 27

Deciphera Pharmaceuticals LLC 27

Eli Lilly and Co 28

Lupin Ltd 28

Mirati Therapeutics Inc 29

Oncobiologics Inc 29

Oncodrone BV 30

OPKO Health Inc 30

R Pharm 30

Redx Pharma Plc 31

Serene LLC 31

Taiho Pharmaceutical Co Ltd 31

Terpenoid Therapeutics Inc 32

Bone Metastasis - Drug Profiles 33

ADM-01 - Drug Profile 33

ALX-0141 - Drug Profile 34

AM-3701 - Drug Profile 36

BKM-1644 - Drug Profile 37

BKM-1740 - Drug Profile 38

BMD-3151 - Drug Profile 39

calcifediol ER - Drug Profile 40

CCX-354 - Drug Profile 46

DCC-3014 - Drug Profile 48

denosumab - Drug Profile 50

denosumab biosimilar - Drug Profile 60

denosumab biosimilar - Drug Profile 61

denosumab biosimilar - Drug Profile 62

denosumab biosimilar - Drug Profile 63

Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer - Drug Profile 64

emibetuzumab - Drug Profile 65

LG-1980 - Drug Profile 68

merestinib - Drug Profile 69

Monoclonal Antibodies to Inhibit SVEP1 for Bone Metastasis - Drug Profile 71

Monoclonal Antibody to Inhibit Connexin 43 for Breast Cancer and Bone Metastasis - Drug Profile 72

OCD-155 - Drug Profile 73

Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Drug Profile 74

RPH-203 - Drug Profile 75

RSF-102 - Drug Profile 76

RSF-103 - Drug Profile 77

sitravatinib - Drug Profile 78

Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile 81

Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology - Drug Profile 82

TAS-115 - Drug Profile 83

Tin-117m-DTPA - Drug Profile 84

TPH-9 - Drug Profile 85

vicrostatin - Drug Profile 86

Bone Metastasis - Dormant Projects 87

Bone Metastasis - Discontinued Products 89

Bone Metastasis - Product Development Milestones 90

Featured News & Press Releases 90

Appendix 100

Methodology 100

Coverage 100

Secondary Research 100

Primary Research 100

Expert Panel Validation 100

Contact Us 100

Disclaimer 101

List of Tables

List of Tables

Number of Products under Development for Bone Metastasis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Bone Metastasis – Pipeline by Ablynx NV, H2 2017

Bone Metastasis – Pipeline by Amgen Inc, H2 2017

Bone Metastasis – Pipeline by Amura Holdings Ltd, H2 2017

Bone Metastasis – Pipeline by BiologicsMD Inc, H2 2017

Bone Metastasis – Pipeline by ChemoCentryx Inc, H2 2017

Bone Metastasis – Pipeline by CSPC Pharmaceutical Group Limited, H2 2017

Bone Metastasis – Pipeline by Deciphera Pharmaceuticals LLC, H2 2017

Bone Metastasis – Pipeline by Eli Lilly and Co, H2 2017

Bone Metastasis – Pipeline by Lupin Ltd, H2 2017

Bone Metastasis – Pipeline by Mirati Therapeutics Inc, H2 2017

Bone Metastasis – Pipeline by Oncobiologics Inc, H2 2017

Bone Metastasis – Pipeline by Oncodrone BV, H2 2017

Bone Metastasis – Pipeline by OPKO Health Inc, H2 2017

Bone Metastasis – Pipeline by R Pharm, H2 2017

Bone Metastasis – Pipeline by Redx Pharma Plc, H2 2017

Bone Metastasis – Pipeline by Serene LLC, H2 2017

Bone Metastasis – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017

Bone Metastasis – Pipeline by Terpenoid Therapeutics Inc, H2 2017

Bone Metastasis – Dormant Projects, H2 2017

Bone Metastasis – Dormant Projects, H2 2017 (Contd..1), H2 2017

Bone Metastasis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Bone Metastasis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports